Marker Therapeutics Profit Margin

Marker Therapeutics (MRKR) currently reports a profit margin of -520617850.61% as of June 2026. That compares with -271.11% in the prior-year period — down 192032325.3% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Marker Therapeutics's profit margin history and peer comparisons.

Marker Therapeutics's profit margin decreased from -271.11% to -520617850.61% — a 192032325.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Marker Therapeutics's profit margin of -520617850.61% is lower than the Healthcare sector average of 21.34%. That is roughly 2440182114.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Marker Therapeutics's current -520617850.61% should be judged against Healthcare norms (sector average: 21.34%) and against MRKR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -520617850.61%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Marker Therapeutics, and consider following MRKR for alerts when major investors trade the stock.